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Abstract
Background: For critically ill patients treated in intensive care units (ICU), two feeding strategies are currently
being advocated, one by American/Canadian and the other by European expert guidelines. These guidelines differ
particularly in the timing of initiating parenteral nutrition (PN) in patients for whom enteral nutrition (EN) does not
reach caloric targets.
Methods/Design: The EPaNIC trial is an investigator-initiated, non-commercial, multi-center, randomized,
controlled, clinical trial with a parallel group design. This study compares early (European guideline) versus late
(American/Canadian guideline) initiation of PN when EN fails to reach a caloric target. In the early PN group, PN is
initiated within 24-48 hours after ICU admission to complete early enteral nutrition (EN) up to a calculated
nutritional target. In the late PN group, PN completing EN is initiated when the target is not reached on day 8. In
both groups, the same early EN protocol is applied. The study is designed to compare clinical outcome (morbidity
and mortality) in the 2 study arms as well as to address several mechanistical questions. We here describe the
EPaNIC study protocol and the statistical analysis plan for the primary report of the clinical results.
Discussion: The study has been initiated as planned on august 01 2007. One interim analysis advised continuation
of the trial. The study will be completed in February 2011.
Trial Registration: ClinicalTrials (NCT): NCT00512122
Background
Nutritional support in ICU patients
It remains unclear whether artificial nutritional support
beneficially affects outcome of critically ill patients. The
route of administration, the delay before initiating such
artificial nutrition, the amount of calories and possibly
a l s ot h et y p eo fn u t r i e n tf o r m u l am a yb eo fi m p o r t a n c e
[1-3].
As compared to parenteral nutrition (PN), enteral
nutrition (EN), and early EN in particular, has been
reported to be associated with less (infectious) complica-
tions [4-6], lower risk for pronounced hyperglycemia [5]
and thus EN could be safer as well as cheaper. However,
relying solely on EN often results in not achieving the
caloric targets [7-9]. Indeed, even in stable intensive
care unit (ICU) patients, early initiation of EN was asso-
ciated with a high incidence of gastrointestinal intoler-
ance and serious adverse events, such as regurgitation,
suspected aspiration or colectasia, which necessitated
stopping of EN [10]. Even after formal implementation
of an evidence-based nutrition protocol in the ICU, the
mean time to administering enteral feeding appeared to
be about 3 days [1]. Furthermore, the mean percentage
of caloric target achieved by day 4 was below 70% [1].
In addition, as physicians are unable to accurately pre-
dict which patient in the ICU will be resuming normal
oral or enteral nutrition within one week after admis-
sion, the risk of underfeeding critically ill patients during
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any medium, provided the original work is properly cited.the first week in ICU is substantial [11]. Indeed in many
patients, solely relying upon EN has shown to result in
underfeeding [7,8]. Underfeeding has been associated
with an increased incidence of infection [12], and with
other complications such as prolonged ventilation, pro-
longed length of stay and pressure ulcers [13,14]. In
spite of such association between malnutrition and
adverse outcomes, it has not been investigated in ade-
quately powered randomized clinical trials (RCT)
whether parenterally completing failing EN early in the
course of critical illness provides an outcome benefit.
Combining PN with EN indeed represents a strategy
to prevent such malnutrition, but has frequently led to
overfeeding [7,15]. Overfeeding has been associated with
increased risk of infection and metabolic disturbances,
such as hyperglycemia, dyslipidaemia and liver dysfunc-
tion, as well as with prolonged mechanical ventilation
[16,17]. Such a risk of overfeeding, however, could be
prevented by using a computer-assisted feeding protocol
via the patient data management systems (PDMS) cur-
rently in use in ICUs, as such system could remind phy-
sicians to reduce the PN supplement proportionally to
the increase in enteral intake. Furthermore, a meta-
analysis demonstrated that elevated blood glucose levels
with early PN as compared with early EN may at least
partially explain more infectious and non-infectious
complications [5,18,19].
Skeletal muscle weakness in ICU patients is a serious
threat for failed weaning from mechanical ventilation
and for hampered rehabilitation. Typically, about one
third of prolonged critically ill patients develop critical
illness polyneuropathy and/or myopathy resulting in
important neuromuscular weakness [20]. Theoretically,
preventing starvation early during critical illness may
partially prevent skeletal muscle catabolism and hereby
prevent substantial muscle wasting. However, aggressive
nutrition did not effectively reduce muscle breakdown
and instead resulted in fat accumulation [21]. Part of
the failure to reduce muscle catabolism with PN could
be related to the concomitant hyperglycemia as recently
shown in an animal model [22,23]. It thus remains
unclear whether prevention of hyperglycemia with insu-
lin during early provision of optimal amounts of calories
with a combination of EN plus PN, could prevent such
complications [15].
Conflicting guidelines and practices
Current American/Canadian as well as European clinical
practice guidelines for nutritional support in the criti-
cally ill strongly recommend that EN be used in prefer-
ence to PN whenever the gastrointestinal tract is intact
and functional.
The American/Canadian guidelines in addition recom-
mend that PN should not be started at the same time
as EN. Also, it is advised that hypocaloric nutrition
should be tolerated during the first week in ICU for
patients who are not malnourished prior to ICU admis-
sion [24,25].
The recent European Society for Parenteral and Ent-
eral Nutrition guidelines for parenteral nutrition in
intensive care recommend the administration of supple-
mental parenteral nutrition within 2 days after ICU
admission to patients who cannot be fed sufficiently via
the enteral route [26]. Such expert opinion is in part
explained by recent data from meta-analyses that
revealed a lower mortality with PN in critically ill
patients [6].
Current guidelines for nutritional support of patients
in the ICU therefore differ substantially among conti-
nents and countries. Such differences are explained by
absence of high level evidence for either of the strategies
applied worldwide and therefore the guidelines are all
largely based upon expert opinion. These differences in
nutritional practices not only indicate the lack of evi-
dence for impact on patient outcome but also represent
important differences in costs for critical care [9,27,28].
Rationale of the study
In view of the 2 different practice guidelines widely
adopted based upon strong expert opinion but in the
absence of high level evidence, there is need for an ade-
quately powered randomized controlled trial comparing
the two nutritional practices.
In a context of prevention of hyperglycemia and while
avoiding overfeeding, a strategy based on early PN com-
pleting EN up to a calculated caloric and protein target
(further referred to as “early PN”) could be superior to
withholding PN during the first week of critical illness
(further referred to as “late PN”) by preventing weakness
and enhancing recovery. Alternatively, withholding PN
during the first week of critical illness ("late PN”) while
advocating early EN may shorten ICU and hospital stay
by avoiding complications of early PN. Finally, clinical
equivalence of the 2 feeding strategies would generate
evidence in favor of withholding PN for one week in
ICU in view of the cost of this intervention. (Figure 1)
PN
EN
EN
Nutritional
Target
EN
EN
Early PN group Late PN group
Nutritional strategy during the first week 
in ICU according to randomisation.
Figure 1 Conceptual cartoon of study design.
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acronym “EPaNIC”, we compare “early PN” with “late
PN” in ICU patients at risk of developing malnutrition
in the ICU. The primary focus of the EPaNIC study is
clinical outcome, more specifically the dependency on
intensive medical care and need for hospitalization as
well as vital status. In addition, a series of mechanistic
studies as well as a long-term follow-up is planned. The
latter however do not form the basis of this manuscript.
Methods/Design
Patient eligibility for inclusion and recruitment
Upon admission to ICU, all adult patients undergo
nutritional screening with the Nutritional Risk Screening
(NRS 2002) score. This is a scoring system developed to
detect the presence of malnutrition and the risk of
developing malnutrition in the hospital [29].
All adult patients admitted to any of the 7 participat-
ing intensive care units, who present with an NRS
score higher or equal than 3, are eligible for inclusion
in the EPaNIC study. The following patients are not
considered eligible for inclusion: patients with a “do
not resuscitate” code at the time of ICU admission,
patients expected to die within 12 hours, patients read-
mitted to ICU after randomization to the EPaNIC trial,
patients enrolled in another trial, patients transferred
from another ICU after a stay of more than seven
days, and patients suffering from ketoacidotic or
hyperosmolar coma on admission. Moreover, patients
with a body mass index (BMI) <17 (kg/m2), patients
with short bowel syndrome treated with home-PN,
patients on home mechanical ventilation, pregnant
or lactating women are not included. Finally,
patients without a clinical indication or with a contra-
indication for a central venous catheter and patients
who are still able to take oral nutrition on ICU admis-
sion or with an NRS score lower than 3 are excluded
from this trial.
Ethical aspects and informed consent
Written informed consent is obtained from the patient
or the closest family member or legal guardian. The
patient or the next of kin can withdraw from the study
at any time, without penalty or impact on treatment.
A register is kept of all patients evaluated for inclusion
and of patients who withdraw from the study. The latter
are clinically followed up without their data being ana-
lyzed in the study.
The study protocol and consent forms were approved
by the Institutional Review Board (IRB) of the Katho-
lieke Universiteit Leuven, University Hospitals (approval
number ML4190) and by the competent Belgian autho-
rities (EudraCT 2007-000169-40). The Jessa Hospitals’
Institutional Review Board IRB (Hasselt) gave positive
advice for the addition of 2 of their ICUs (Unit A
and C) at the study site Jessa Hospitals.
Data collected at study entry
At baseline, data on demographic and clinical character-
istics of the patients are obtain e d .D i s e a s es p e c i f i cr i s k
scores are calculated and co-morbidities and known use
of important medications prior to admission are noted:
these comprise, among others, Acute Physiology and
Chronic Health Evaluation II score (APACHE II), pre-
sence of cancer, diabetes mellitus, kidney failure
(Chronic Kidney Disease score), liver failure (Child clas-
sification), COPD (Gold classification), and heart failure
(New York Heart Association Functional Classification ≥
2). Sepsis upon admission is labeled as such using modi-
fied Bone criteria [30,31].
Randomization
The study has a prospective, randomized, controlled,
parallel-group design. Consecutive patients are randomly
assigned to one of the two treatment study groups,
labeled “Early PN” or “Late PN”,u s i n gs e q u e n t i a l l y
numbered, sealed and opaque envelopes. Upon addition
of the study site Jessa Hospitals, these envelopes were
replaced by an identical digital system allowing central
computerized randomization. Patients are stratified per
study site according to 17 primary diagnostic categories
on admission. The stratified groups were labeled as
follows:
I Medical-ICU admissions: (a) respiratory; (b) cardio-
vascular; (c) renal; (d) hematological/oncological; (e) GI/
hepatic; (f) metabolic; (g) neurological (h) other;
II Surgical-ICU admissions according to referral disci-
pline (a) cardiac surgery (elective or urgent surgery)
(b) complicated thoracic surgery; (c) complicated vascu-
lar surgery (d) complicated abdominal and pelvic sur-
gery (e) complicated neurosurgery (f) trauma and burns
(g) transplantation (h) neurological disease (i) other.
Randomization - in a one to one allocation ratio - was
performed using permuted blocks of 10, information
that remained unknown to bed-side physicians and
nurses, responsible for patient recruitment and therapy
assignment.
a. Randomized interventions
“Early PN” Patients randomized to the “early PN”
group receive Glucose 20% at 40 ml/hr on the admis-
sion day. PN [OliClinomel
® or - when fat free PN is
indicated - Clinimix
® (Baxter, Brussels Belgium)] is
initiated the second morning in ICU. The amount of
PN to be given on any particular day is the difference
between calculated caloric needs and the calories deliv-
ered by EN the previous 24 hours. Caloric needs calcu-
lations are based on corrected ideal body weight, age
and gender [32] moreover, we defined an absolute
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of calculated caloric needs, PN is stopped. When the
patient is able to eat, the PN is reduced and eventually
stopped. Whenever enteral or oral intake falls below
50% of calculated caloric needs, the PN is restarted.
“Late PN” Patients randomized to the “late PN” group
receive a volume of Glucose 5% that is required to
obtain adequate hydration taking into account the
volume of EN that is being delivered. If enteral feeding
of at least 80% of the calculated calories is not possible
after 7 days in ICU, PN is initiated on day 8.
b. Common strategy for early EN in both study arms
In all patients unable to eat on the second evening of
ICU stay and without formal contraindication, EN is
initiated with the patients in semi-recumbent position.
The increase of EN volume, the use of gastroprokinetics
and duodenal feeding tubes are described in the stand-
ing-orders for EN. Parenteral trace elements, minerals
and vitamins are administered in all patients of both
groups as clinically indicated.
In both study groups, blood glucose levels are targeted
to 80-110 mg/dl with continuous insulin infusion [18].
Blood glucose and potassium are monitored every 1 - 4
hours on the bloodgas-analyzer (ABL-Radiometer
®)
using arterial blood samples.
The volumes of PN and EN to be given according to
the treatment group are calculated by the PDMS (Meta-
vision
®,i M D s o f t ,B o s t o n ,U S A ) .T h e s ec a l c u l a t i o n sa r e
based on the nutritional intake during the previous day
and the clinical evolution of the patient. Patients are
weaned from the ventilator according to a standardized
guideline used in all participating ICUs. End-of-care
decisions in patients for whom further intensive care is
considered to be futile are taken in consensus by a
group of two senior ICU physicians and the referring
specialist.
Handling of re-admissions to ICU
Patients who are re-admitted to ICU after a participa-
tion in EPaNIC are not eligible for re-inclusion. Patients
who are readmitted to the ICU within 48 hours of dis-
charge and who are still within the 7 days time window
of the initial randomization receive the nutrition-
schedule they were assigned to during the initial ICU
admission. Patients readmit t e dl a t e rw i l lb ef e da tt h e
discretion of the attending physician.
Blinding of treatment allocation
Treating physicians and patients could obviously not be
blinded. However, all outcome assessors, which are
investigators not directly involved in the patients care
(such as statisticians, laboratory personnel, infectious
disease specialists, pathologists, physiotherapists involved
in the strength measurement, electrophysiologists) as
well as physicians and nurses in the conventional wards,
are blinded to treatment allocation.
Data collection following recruitment
All medications received by the patients during ICU stay
are registered. Every day the amount of kilocalories,
lipids, proteins, carbohydrates delivered by either PN or
EN are calculated from the PDMS in an automated
manner and entered into the case report form (CRF).
For calculation of the energy requirements, 50% of the
gastric residual volume, which is being discarded by the
bedside nurses, is considered to be EN calories not
absorbed by the patient. Interruptions of EN delivery
and predefined digestive intolerance are registered daily.
Mechanical complications such as displacement or
obstruction of the enteral feeding tube or the central
venous catheters; and clinical complications such as
pneumothorax, hemothorax and subclavian or carotid
artery puncture are recorded daily. Number of ICU days
with a central line in situ is also noted. In addition we
record the need for and the number of days of mechani-
cal ventilatory support, of mechanical and pharmacolo-
gical hemodynamic support, of renal replacement
therapies and placement of tracheostomy.
Blood samples (a subset of which are immediately
stored on ice for future endocrinological measurements)
are taken upon ICU admission and daily at 06:00 h until
discharge from ICU or death. All whole blood glucose
levels are measured on arterial blood using a blood gas
analyzer on each ICU and are registered for later calcu-
lation of glucose metrics.
Analyses on blood and urine for the primary clinical
analyses include routine chemistry, hematology, and
markers of inflammation. Further metabolic, endocrine
and inflammatory measurements planned on stored
samples in the context of mechanistic analyses fall
beyond the scope of this paper. In addition, for later
mechanistic studies, a random selection of patients are
prospectively and repeatedly screened for the presence
of sludge or cholecystitis on ultrasonography.
All new infections of the lungs, the blood stream, the
urinary tract and wounds are recorded by an infectious
disease specialist. Bacteraemia is further classified by
responsible pathogen and as catheter related blood
stream infection versus other bacteraemia [33,34].
For further mechanistical and exploratory studies, ela-
borated muscle strength testing, electrophysiological
examination, skeletal muscle and adipose tissue biopsies
and radiological evaluation of skeletal muscle and adi-
pose tissue compartments are performed after specific
or additional informed consent from the patient or the
legal guardian. These analyses will be repeated at differ-
ent time intervals, also after hospital discharge, on con-
dition of obtaining adequate additional funding. The
statistical plan for all these analyses fall beyond the
scope of this manuscript. Furthermore, as far as practi-
cally feasible, every patient is approached just prior to
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(6 MWD) [35] by a trained physiotherapist and for scor-
ing the activity in daily life (ADL). The long-term fol-
low-up will include sending out a Medical Outcomes
Study 36 items short form questionnaire to all patients.
Data conservation and processing
Data are collected electronically in an anonymized CRF,
unambiguously linked to the source file. Data is manu-
ally transferred (and checked for accuracy) into the CRF
by the clinical research assistance team on a daily basis
from the ICU PDMS and the Leuven University Hospi-
tals Clinical Working Station (KWS). Extensive range
and consistency checks are performed by the study
monitor. Vital status at 90 days will be recorded for all
patients, eventually via the Belgian National Registry
when this information is not available in the hospital
information system.
Trial Organisation
Administrative and legal aspects
The sponsor (K.U.Leuven) provides direct access to the
CRF, the source data and the study master file for moni-
toring, Independent Ethics committee review and regula-
tory inspection. The sponsor established an independent
data safety monitoring board (DSMB) (RB, PL and JV).
The sponsor appointed one monitor (PW). The monitor
verifies that the trial is performed in accordance to the
protocol as described in the European Medicine Agency’s
“Note for guidance on good clinical practice CPMP/ICH/
135/95.” as well as the Declaration of Helsinki. Monitor-
ing is performed and reported following the sponsor’s
standing operating procedures. No fault insurance is cov-
ered by Fortis Corporate Insurance NV.
Trial Coordination
The clinical research team guarantees a daily follow up
of patient screening and inclusion, availability of
requested clinical data in the clinical patient files and
protocol compliance. Every non-compliance to the pro-
tocol and other questions or problems are reported to
the study monitor (PW) and discussed with the princi-
pal investigators. Serious Adverse Events (SAE) are
reported to the study sponsor (K.U.Leuven). The study
monitor (PW) regularly provides the sponsor with
reports on inclusions and SAE. Regular meetings are
organized with principal investigators and clinical
research team to discuss the daily progression of the
research project.
Protocol implementation
The protocol was and is being instructed (by MC) to all
clinical medical and paramedical staff trough frequent
teaching sessions, clinical feedback rounds and posters
representing the study flow. (Figure 2) The protocol
decision support is integrated into the ICU patient data
management system, facilitating the prescription of the
exact amounts of PN and EN according to protocol and
clinical evolution. (WDB, DC, GM and MC)
Interim analysis
As both the nutritional strategies investigated in this
trial are current ICU practices, the DSMB judged that
repeated interim analyses for efficacy were not required.
One formal “safety” interim analysis was planned after
patient number 1500 left the ICU, during which the
independent DSMB had access to un-blinded results on
ICU mortality, hospital mortality and serious adverse
events from 1495 patients. The DSMB judged that there
was no reason to prematurely stop the clinical trial for
safety reasons, or to perform more safety interim ana-
lyses and decided that the randomization and nutritional
therapy study had been executed as planned in the study
protocol. The DSMB advised to continue the study to
completion, under monitoring of the serious adverse
events. Because the primary efficacy endpoint was not
analyzed, no correction of the significance level at the
final analysis is necessary.
Statistical analysis plan
We here report the statistical analysis plan for the pri-
mary clinical report of the primary and secondary clini-
cal endpoints of this RCT. These include the acute
clinical effects of the intervention during ICU stay and
hospitalization, including survival up to 90 days after
randomization. Additional long-term outcomes, further
mechanistic and exploratory analyses of the effect of
early PN versus late PN will be reported separately and
statistical details for these additional studies fall beyond
the scope of this manuscript. The additional outcomes
comprise, among others, results of elaborated peripheral
and respiratory muscle testing and electrophysiological
signs of myopathy-neuropathy, radiographic and micro-
scopic evaluation of muscle and adipose tissue volumes
and composition, biochemical and molecular analyses of
skeletal muscle and adipose tissue biopsies, endocrine
function, liver and bile function. Furthermore, a health
economy analysis is planned.
General rules of the statistical analyses
A consort diagram will be reported. (Figure 3) All ana-
lyses will be performed on a full intention-to-treat basis.
The data file will be finalized 90 days after inclusion of
the last patient.
To assess compliance with the study protocol, the
amounts of PN and EN actually given in the two study
groups during the intervention window of 8 days will be
reported as absolute numbers and percentages of target
calories.
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and percentages. Continuous variables will be summar-
ized by use of either mean or standard deviations (SD)
or median and interquartile range as appropriate.
Baseline and outcome variables will be compared
using Student’s t-test, (exact) Chi-square test and
Mann-Whitney-U test, as appropriate.
All outcomes will be analyzed in an uncorrected man-
ner as well as jointly corrected for risk factors (type and
severity of illness, age, BMI and NRS categories). Type
of illness will comprise the diagnostic categories, as stra-
tified and grouped per organ system, as well as the pre-
sence or absence of a history of cancer. As severity of
illness score for this correction, APACHE II will
Figure 2 Trial procedures flow sheet.
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Page 6 of 11be used. BMI will be categorized as <20, 20-<25, 25-<30,
30-<40 and ≥40 kg/m2. Applicable NRS categories for
this study are 3, 4, 5, 6 and 7. In case certain categories
would appear underrepresented, such patients will be
assigned to the next category in rank or previous cate-
gory if it is the last category that is underrepresented.
A priori defined subgroup analyses will be performed
for BMI and NRS subcategories. These subgroup ana-
lyses are based on the rationale that BMI has been
reported to be associated with different risk of outcome
in different types of ICU patients which may be due to
different handling of nutritional substrates [36-38].
Assessed for eligibility (n) 
(every adult admission 
to one of the 7 ICU's)
Randomized (n)
Randomized to  Early PN (n)
• Received intervention (n)
• Discontinued intervention (n)
-P a t i e n t / s u r r o g a t e  r e q u e s t
- Protocol violation
Lost to follow up (n)
(Unable to locate patient)
Analyzed (n)
All patients randomized to 
Early PN
Randomized to  Late PN (n)
• Received intervention (n)
• Discontinued intervention (n)
-P a t i e n t / s u r r o g a t e  r e q u e s t
- Protocol violation
Lost to follow up (n)
(Unable to locate patient)
Analyzed (n)
All patients randomized to 
Late PN
Excluded (n)
Reasons for exclusion 
Figure 3 CONSORT flow diagram.
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or obesity (BMI 25 to <40) versus all other BMI cate-
gories (undernourished and normal BMI [BMI <20 and
BMI 20-<25] or morbid obesity [BMI ≥ 40]). Therefore
BMI will be dichotomized as such to optimize the
power of this subgroup analysis. Also patients at higher
risk of malnutrition may respond differently to the feed-
ing strategies. Therefore, in this subgroup analysis, NRS
will be dichotomized separating the highest risk patients
[NRS ≥ 5] from the moderate risk patients [NRS 3 and
4]. Another a priori defined subgroup analysis will be
performed for patients admitted to ICU after emergency
or elective cardiac surgery as compared with all other
patients. The shorter time in ICU of this subgroup may
result in the early PN group receiving predominantly
extra glucose 20% infusion, without lipids and amino-
acids, as compared with the glucose 5% in the late PN
group, which may evoke a different response than the
full week combined parenteral nutrition. As sepsis is
known to aggravate the metabolic disturbances evoked
by early PN, a priori subgroup analysis is planned for
patients with and without sepsis upon admission. These
a priori defined subgroup analyses will be performed for
the primary and safety endpoints without correction for
other variables. To test for interaction between the iden-
tified subgroups and the studied intervention, a multi-
variable analysis (logistic regression or proportional
hazard analysis as appropriate) will be performed for
each subgroup variable separately and with the subgroup
variable, the intervention and their interaction in the
model. The interaction will be tested at a significance
level of 0.1.
The first clinical report will analyze the impact of the
nutritional strategies on safety (among which mortality),
primary and secondary efficacy endpoints.
For all endpoints, differences will be considered statis-
tically significant whenever the p-value reaches 0.05 or
lower without correction for multiple testing.
Safety endpoints
Safety endpoints comprise vital status (mortality 90 days
after randomization independent of ICU and hospital
discharge status, hospital mortality, ICU mortality and
proportion of patients discharged alive from ICU within
8 days), hypoglycemia, serious adverse events and com-
plications related to the mode of nutrition.
Survival up to 90 days after randomization in both
treatment groups will be compared by Kaplan Meier sur-
vival plots. The impact of “late PN” versus “early PN” will
be analyzed, with and without correction for age, BMI &
NRS categories and type and severity of illness, by Cox
proportional hazard analysis. Vital status up to 90 days
predictably will be traceable for virtually all patients via
the National Registry, loss to follow-up will likely not be
present except for some patients who will have a resi-
dence outside the Belgian territory. In addition, we will
record vital status at ICU and hospital discharge and
90 days after randomization, and will analyze differences
with Chi-square testing. All analyses will be performed in
the intention to treat population. Correction of such dif-
ferences in ICU and hospital mortality for age, BMI &
NRS categories and type and severity of illness, will be
performed using a multivariable logistic regression analy-
sis, on condition of the absence of co-linearity between
risk factors. Frequencies and percentages for both study
arms will be presented together with odds ratios and 95%
confidence intervals. As the randomized study interven-
tion only takes place during a time window up to the 8
th
day in ICU, we also plan to analyze early lethality within
this time window in the intention to treat population as
part of the safety analysis.
As patients not receiving early PN may be considered
at increased risk for hypoglycemia, we will report for
both groups the number of patients experiencing hypo-
glycemia <40 mg/dl during the time window of the ran-
domized intervention. Hypoglycemia resistant to
parenteral glucose administration is considered as a SAE
and the incidence during the time window of the rando-
mized intervention will be reported for both groups. In
addition, overall blood glucose control during the time
window of the intervention will be compared using daily
morning blood glucose as well as daily maximal and
minimal blood glucose. More sophisticated glucose
metrics will be analyzed (among others hyperglycemic
index, hypoglycemic index en glycemic penalty index)
but such metrics fall beyond the scope of this initial
report. Also, requirement of insulin will be compared.
Safety issues also comprise the occurrence of feeding-
mode related complications during the time window of
the intervention. Therefore, occurrence of these compli-
cations (digestive intolerance, complicated insertion of
feeding tubes, pneumothorax, hemothorax and subcla-
vian or carotid artery puncture, occlusion or displace-
ment of central venous catheters or gastric feeding
tubes) will be reported for both treatment groups.
Primary efficacy endpoint
The primary efficacy endpoint for this RCT is the time to
discharge alive from ICU. As the time of ICU discharge
to the regular ward may be affected by the availability of
beds on the regular wards, which could induce bias, we a
priori decided to analyze “time to discharge from ICU” as
“time to ready for discharge from ICU”. A patient is con-
sidered “ready for discharge” as soon as all clinical condi-
tions for ICU discharge have been fulfilled (no longer in
need for vital organ support and receiving at least 2/3 of
the caloric requirements as oral feeds) or earlier when
the patient is actually sent to a regular ward.
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Kaplan Meier plots, with ICU non-survivors censored
beyond the longest ICU stay of survivors and censoring
time of patients still in the ICU at closing of the datafile
(90 days after last patient inclusion) over both treatment
groups. The impact of “late PN” versus “early PN” will
be analyzed, with and without correction for age, BMI
& NRS categories and type and severity of illness, by
Cox proportional hazard analysis. The distribution of
t h ea c t u a lt i m et od i s c h a r g ef r o mI C Uw i l lb er e p o r t e d
for ICU-survivors and ICU-non-survivors separately. In
view of the time window of the randomized intervention
in ICU, also the proportion of patients staying beyond
8 days in ICU will be reported.
Secondary efficacy endpoints
All analyses will be performed uncorrected as well as
corrected for age, BMI & NRS categories type and
severity of illness. Time to event analysis will be ana-
lyzed similarly as the primary endpoint. Proportion of
patients requiring support of vital organ functions and
distribution of duration of support will be analyzed by
non-parametric or parametric testing depending on the
normality of the distribution in the subgroup of patients
for which support was needed. Proportions will be com-
pared using chi-square testing. Results of repeated mea-
surements will be analyzed using an appropriate model
for longitudinal data.
a. Time to discharge alive from the hospital, with
patients still in the hospital at closing of the data file
censored at that time point; patients transferred to
another hospital censored on the day of transfer;
and non-survivors censored beyond the longest hos-
pital stay of survivors and censoring time of patients
still in the hospital at closing of the data file
(90 days after last patient inclusion) over both treat-
ment groups.
b. Time to final (alive) weaning from mechanical
respiratory support with patients still on mechanical
respiratory support at closing of the data file being
c e n s o r e da tt h a tt i m ep o i n ta n dI C Un o n - s u r v i v o r s
censored beyond the longest duration of mechanical
respiratory support of the survivors and censoring
time of patients still on mechanical respiratory sup-
port at closing of the data file (90 days after last
patient inclusion) over both treatment groups.
c. Kidney failure: Proportion of patients in need for
renal replacement therapy (RRT) during ICU stay;
distribution of duration of RRT (for those patients
requiring RRT); proportion of patients with a post-
randomization diagnosis of new kidney injury/failure
(defined by modified Risk, Injury, Failure, Loss, and
End-stage Kidney (RIFLE) classification criteria as a
plasma creatinine doubling or more during ICU
stay) in both treatment groups.
d. Need for pharmacological or mechanical hemody-
namic support during ICU stay, and duration of
such need. In addition, time to final (alive) weaning
from all pharmacological or mechanical hemody-
namic support in ICU will be analyzed, with ICU
non-survivors censored beyond the longest duration
of pharmacological or mechanical hemodynamic
support of the survivors and censoring time of
patients still on such support at closing of the data
file (90 days after last patient inclusion) over both
treatment groups.
e. Need for a tracheostomy during ICU stay.
f. Occurrence of infections during ICU stay: Number
of patients with new infections and types of infection
as specified in the study protocol and the duration of
any antibiotics therapy initiated after randomization
for those patients requiring antibiotics.
g. Cholestasis and liver dysfunction: Proportion of
patients during the time window of the intervention
and during the whole ICU stay presenting with cho-
lestasis, defined as total bilirubinemia above 3 mg/dl
or an increase to 150% of baseline value of gamma-
glutamyltransferase or alkaline phosphatase. An
increase of alanine or aspartate transaminases higher
than 3 times the upper limit of normal will be con-
sidered as a marker of liver cytolytic damage. Pro-
portion of patients presenting with such liver
cytolytic damage during the time window of the
intervention and during the whole stay in ICU will
be compared. More subtle changes in liver enzymes
will be analyzed by comparing the distribution of the
h i g h e s tv a l u e sa n dt h et i m ec o u r s eo ft h ed a i l y
measurements.
h. Inflammation: Effect of the intervention on
inflammation will be analyzed by comparing the dis-
tribution of the highest value reached during ICU
stay and changes from baseline to the highest value
and by comparing time profiles of daily C-Reactive
Protein values.
i. Distribution of 6 MWD at hospital discharge in
both treatment groups will be compared, as well as
the proportion of patients unable to perform the test
due to clinical reasons.
j. Proportion of patients independent for all ADL
functions in both groups will be compared at hospi-
tal discharge. Hospital non-survivors will be analyzed
as fully dependent for all functions.
Sample size calculation
The sample size was calculated in order to detect, with at
least 80% power and 95% certainty, an increase or
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[from a baseline assumed ICU stay of 8 ± 13 (mean ±
SD) days and a median of 4 days assuming log-normal
distribution; power calculated using one-tailed Student’s
t-test using the mean and SD for an increase and a
decrease with 1 day and confirmed with two-tailed Stu-
dent’s t-test after log transforma t i o n ] .T oc o n c o m i t a n t l y
detect with at least 70% power and 95% certainty an ICU
mortality increase or decrease of 3% (assuming a baseline
mortality of 20% anticipating a Medical-ICU/Surgical-
ICU patients fraction of 25/75%; power calculated with
two-tailed chi-square testing), a sample of 4640 (patients
2320 per arm) was considered necessary. We plan to cal-
culate the true power of the study for detection of any
eventual smaller difference in these outcomes.
Discussion
The study has been initiated as planned on august 01
2007. One interim analysis advised continuation of the
trial. The study will be completed in February 2011.
A significant difference in the safety and/or efficacy end-
points will provide important evidence for optimizing
clinical patient care. Also a neutral result will provide
important insight, as this would mean that clinicians
can safely withhold PN in all comparable patients during
the first week of ICU stay, which has an impact on
expenses for critical care.
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